Project Grant R01DK143190
- This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,232,846 to the Scripps Research Institute to study the mechanisms of initiation and progression of beta cell death in type 1 diabetes. The key objectives are to build a histocompatible vascularized micro-organ platform that can integrate patient-derived immune cells to...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), through the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $153,554 Project Grant to the Beckman Research Institute of the City of Hope. This grant, awarded on September 15, 2025, supports research aimed at unveiling novel targets for type 1 diabetes therapy by investigating the functional heterogeneity of pancreatic alpha cells and their interactions with beta and delta...
- This federal Cooperative Agreement award, with a total funding amount of $1,207,770.00 and an award date of January 1, 2025, was granted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award will support research to investigate the role of genetically-controlled thymic epithelial cell (TEC) and hematopoietic stem cell (HSC) abnormalities in driving the development...
- This federal Cooperative Agreement award of $1,786,925.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to investigate the role of inefficient RNA editing in triggering an innate immune response that leads to beta cell death and the development of type 1 diabetes. The award will fund a project led by the University of Pennsylvania to evaluate...
- This $291,949 Project Grant was awarded on September 15, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant was awarded to Biosettia Inc. (UEI: GZM5S2UYEGD2) located in San Diego, CA to support research aimed at using deep sequencing to measure variants of the endogenous retrovirus (ERV) GAG gene as potential biomarkers for type 1 diabetes. The project seeks...
- This Cooperative Agreement award, in the amount of $816,325.00, was granted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award will support a collaborative research project to optimize and evaluate novel small molecule "PAIR" inhibitors that target the unfolded protein response (UPR) pathway in pancreatic beta cells, with the goal of preventing and...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $621,794 Project Grant to Islex Therapeutics, LLC on August 1, 2025. The grant supports the preclinical development of a therapeutic antibody for treating type 1 diabetes (T1D), a chronic autoimmune disease affecting approximately 1.5 million Americans. The objective is to establish proof-of-principle for a humanized...
- This $2,263,983 Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to develop "engineered regulatory T cells (Tregs)" as an immunotherapy for type 1 diabetes. The central goal is to create antigen-specific Tregs that can more effectively suppress the autoimmune destruction of insulin-producing beta cells. The research...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $235,403 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Johns Hopkins University. The funding will support the development of a membrane-reconstituted ZNT8 biosensor to detect cell-surface ZNT8 autoantibodies in the peripheral blood of patients with type-1 diabetes. This novel bioanalytical tool aims to enable the early detection of islet...
- This federal Project Grant award of $568,075.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award to Brigham Young University aims to determine the role of the transcription factor NR4A1 in the pathways that expand functional beta cell mass, which is critical for treating type 1 and type 2 diabetes. The research seeks to understand how NR4A1 is...
This federal Project Grant award of $801,662, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research by the Scripps Research Institute to investigate the early phase of type 1 diabetes. The key objectives are to characterize the antigen-presenting cells associated with pancreatic islets during the pre-diabetic stage in mice, using advanced techniques like transgenic mouse models, cell tracking, and spatial transcriptomics. This research aims to provide insights into the initiation of autoimmunity in type 1 diabetes and inform potential therapeutic interventions during the pre-clinical phase of the disease. The award period runs from August 15, 2025 to June 30, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $801.7k | 8/14/25 |